Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)
ID: 353243Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $4M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353243

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-010.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Feasibility of Novel Diagnostics for TB in Endemic Countries" (FEND for TB), aimed at enhancing tuberculosis (TB) diagnostics in regions where the disease is prevalent. This initiative seeks to evaluate early-stage diagnostic tests and strategies, particularly those targeting vulnerable populations such as people living with HIV, while adhering to existing clinical algorithms. The total funding available for this opportunity is approximately $5.5 million, anticipated to support 1-2 awards over a five-year period, with applications due by June 29, 2024. Interested applicants can find more information and submit their proposals electronically through Grants.gov, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-010-Full-Announcement.html
    RFA-AI-24-010.html
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Feasibility of Novel Diagnostics for TB in Endemic Countries" (FEND for TB) to enhance tuberculosis (TB) diagnostics in countries where TB is prevalent. The aim is to evaluate early-stage diagnostic tests and strategies, including those targeting specific populations like people living with HIV. This funding opportunity (RFA-AI-24-010) is open for applications from eligible organizations, with a total of $5.5 million anticipated for 1-2 awards over five years. The applications must propose innovative early-stage technologies and include detailed evaluation plans, along with demonstrating collaboration with clinical sites in endemic areas. Critical topics of interest include point-of-care diagnostics, non-sputum specimen analysis, and rapid drug susceptibility testing. Applications will not be considered if they involve clinical trials or the establishment of new clinical infrastructure. The review process will evaluate the significance, innovation, and approach of the proposed projects. Eligible applicants include a broad range of institutions and organizations, including higher education institutions, non-profits, and foreign organizations. All applications must comply with NIH guidelines and be submitted electronically through Grants.gov, with a due date of June 29, 2024.
    Similar Opportunities
    Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment in both adults and children, particularly focusing on individuals with and without HIV. This initiative encourages innovative epidemiological and observational studies to better characterize post-TB lung disease (PTLD) and its associated health impacts, utilizing existing cohorts of TB participants. Interested applicants, including higher education institutions, non-profits, and government entities, must adhere to specific guidelines for submission through the NIH ASSIST system, with applications accepted until May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Approaches for TB Prevention and Case Finding to END TB
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is forecasting a federal grant opportunity titled "Innovative Approaches for TB Prevention and Case Finding to END TB." This initiative aims to develop, implement, and evaluate innovative strategies for tuberculosis (TB) prevention and case finding, focusing on high-burden settings and vulnerable populations, including those living with HIV, children, and economically disadvantaged individuals. The total estimated program funding is $5 million, with an award ceiling of $1 million for up to two cooperative agreements, and applications are expected to be submitted electronically by February 27, 2025. Interested applicants can reach out to Hoang Dang at 404.639.8965 or via email at hdang@cdc.gov for further information.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection," aimed at supporting research into the mechanisms of host cell death related to Mycobacterium tuberculosis (Mtb) and HIV co-infections. The initiative seeks to identify immune targets for the development of host-directed therapies by studying both inflammatory and non-inflammatory cell death pathways, emphasizing the need for multidisciplinary research teams that may include experts in HIV, TB, cell biology, and oncology. This grant does not have a funding cap, but proposals must align with project needs, and the maximum project period is five years. Interested applicants, including various educational and nonprofit institutions, must submit their applications by December 7, 2024, through Grants.gov, adhering to the NIH Grants Policy Statement. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Tuberculosis Elimination and Laboratory Cooperative Agreement
    Active
    Centers for Disease Control - NCHHSTP
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement titled "Tuberculosis Elimination and Laboratory Cooperative Agreement" to support tuberculosis (TB) prevention and control activities at state and local levels. The primary objective of this funding is to reduce TB morbidity and mortality by enhancing public health infrastructure for TB disease surveillance, outbreak response, and laboratory testing, with a focus on preventing the transmission of M. tuberculosis and progression from latent TB infection to active disease. This funding is crucial for strengthening public health responses to TB, which remains a significant health threat, particularly in vulnerable populations. The estimated total program funding is $374,456,055, with an expected 57 awards to be made. Applications must be submitted electronically by September 9, 2024, and interested applicants can contact Martha Boisseau at mboisseau@cdc.gov for further information.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    TB-HIV Community-Led Monitoring
    Active
    Philippines USAID-Manila
    The Philippines USAID-Manila is offering a federal grant opportunity titled "TB-HIV Community-Led Monitoring," aimed at improving health outcomes for tuberculosis (TB) and HIV/AIDS clients through community-led monitoring activities. The initiative seeks to enhance community leadership, strengthen data collection and analysis platforms, and empower community-based organizations to advocate for health system improvements at both national and local levels. This funding opportunity is restricted to local Philippine organizations, with a total award amount of $2,500,000, and the application deadline is September 10, 2024. Interested applicants can reach out to Aileen Ferrer at manila-roaa-rfa@usaid.gov for further information.
    Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Promoting Innovative Research in Treponema pallidum Pathogenesis" (R21 Clinical Trial Not Allowed), aimed at supporting exploratory research to enhance understanding of the pathogenesis of Treponema pallidum, the bacterium responsible for syphilis. This initiative is particularly relevant given the rising rates of sexually transmitted infections (STIs) and the increase in congenital syphilis cases, emphasizing the need for innovative research techniques to lower barriers in this field. The total funding commitment for Fiscal Year 2025 is $2 million, with plans to award 4 to 6 grants, allowing applicants to request budgets up to $275,000 for projects lasting no more than two years. Interested applicants should submit their proposals by November 4, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Strengthening comprehensive HIV and TB services and health systems in high-burden areas of Namibia under the President's Emergency Plan for AIDS Relief (PEPFAR)
    Active
    Centers for Disease Control-GHC
    The Centers for Disease Control and Prevention (CDC) is forecasting a cooperative agreement opportunity aimed at strengthening comprehensive HIV and TB services and health systems in high-burden areas of Namibia under the President's Emergency Plan for AIDS Relief (PEPFAR). This initiative seeks to enhance facility- and community-based service delivery for TB, HIV, and related conditions, supporting the Ministry of Health and Social Services (MOHSS) in overseeing government-led programs, including quality management, monitoring, and public health response. The program is crucial for improving health outcomes in Namibia, with an estimated total funding of $15 million for the first fiscal year, and is expected to result in decreased incidence of HIV and TB, improved health data access, and enhanced government capacity to respond to health threats. Interested applicants can reach out to Emily Dale at (404) 639-8880 or via email at pepfarfoas@cdc.gov, with applications due by February 17, 2025, and awards anticipated by September 30, 2025.